Antihypertensive Dosing Trials Could Have Three-Arm, No-Placebo Design
Antihypertensive drug trials incorporating three dose-ranging arms and no placebo group would give a better picture of a drug's entire dose-response relationship than current fixed-dose studies, FDA Cardio-Renal Drug Products Director Raymond Lipicky, MD, told FDA's Cardiovascular & Renal Drugs Advisory Committee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth